CMB International Securities | Equity Research | Company Update



招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Ban

Goertek (002241 CH)

Strong 4Q20 with better margins; Maintain BUY

Goertek pre-announced FY20 revenue/net profit growth of 64%/123% YoY, which reached upper end of its prior earnings guidance (+115-125% YoY). We maintain our positive view on Goertek's outlook backed by upcycle of AirPods /Watch/HomePod, better product mix and recovery of AR/VR demand. We raised FY21E/22E EPS by 16-18% to reflect stronger revenue and fine-tuned margins. Our new TP of RMB46.9 is based on lowered 35x FY21E P/E (vs prior 40x), given recent weaker sector sentiment. We believe stock price pullback on recent mgmt. changes provides good buying opportunity given Goertek's product roadmap and high earnings visibility of 36% FY20-22E EPS CAGR. Maintain BUY.

- Strong 4Q20 results on AirPods momentum and improving yield. Goertek reported upbeat 4Q20 earnings with revenue/net profit of RMB22.9bn/838mn, up 108%/184% YoY. We attribute this to 1) higher share and improving yield for AirPods, 2) stronger AR/VR products (new Oculus), and 3) better demand for new products (AirPods Max, HomePod mini). For FY20, we estimate revenue from precision components/ hearables (AirPods/Homepod)/ smart products (watch, VR) grew 20%/65%/59% YoY.
- 2021 Outlook: AirPods and AR/VR as dual growth engines. We estimate AirPods shipment will grow 45%/22% YoY to 94mn/115mn in FY20E/21E, and Goertek's share allocation will expand from 23% in FY20 to 37%/41% in FY21/22E, driving AirPods revenue growth of 103%/23% YoY. in addition, we expect Goertek VR/AR segment will regain traction with 40%/30% YoY growth in FY21/20E, backed by new product cycle from Oculus Quest and Sony PSVR in 2H20E.
- Share repurchase program announced. Goertek announced a new share repurchase program of RMB500mn-1bn with price no more than RMB39.0 per share, equivalent to 12.82mn-25.64mn share and 0.39-0.78% of its total shares outstanding. We believe the share buyback signaled mgmt.'s strong confidence about the company's outlook.
- Maintain BUY with new TP of RMB46.9 We revised up our FY21-22E EPS by 16-18% to reflect stronger revenue and fine-tuned margins. Our FY21/22E EPS are 11%/7% above consensus, and our new TP of RMB46.9 is based on lowered 35x FY21E P/E (vs prior 40x), due to recent weaker sector sentiment. We believe recent correction offers good opportunity to accumulate the stock.

Earnings Summary

(YE31Dec)	FY18	FY19	FY20E	FY21E	FY22E
Revenue (RMB mn)	23,751	35,148	57,613	84,439	102,551
YoY growth (%)	(7.0)	48.0	63.9	46.6	21.5
Net income (RMB mn)	868	1,281	2,855	4,384	5,329
EPS (RMB)	0.27	0.40	0.89	1.34	1.63
YoY growth (%)	(60.3)	48.1	122.5	50.4	21.6
Consensus EPS (RMB)	NA	NA	0.87	1.20	1.5
P/E (x)	123.0	83.0	37.3	24.8	20.4
P/B (x)	7.1	6.7	6.0	5.0	4.3
Yield (%)	0.3	0.3	0.7	1.0	1.2
ROE (%)	6	7.9	15.6	20.3	20.8
Net gearing (%)	37	19	33	35	26

Source: Company data, Bloomberg, CMBIS estimate

BUY (Maintain)

Target Price RMB46.9
(Previous TP RMB46.0)
Up/Downside +41.0%
Current Price RMB33.2

China Technology Sector

Alex Ng

(852) 3900 0881 alexng@cmbi.com.hk

Lily Yang

(852) 3916 3716 lilyyang@cmbi.com.hk

Stock Data

Mkt. Cap. (RMB mn)	110,278
Avg. 3mths t/o (RMB mn)	3,775.34
52W High/Low (RMB)	50.23/
	14.82
Total Issued Shares (mn)	3,322

Source: Bloomberg

Shareholding Structure

Weifang Geer Group	17.99%
Jiang Bin	11.51%
Jiang Long	6.02%
Source: Bloomberg	

Share Performance

	Absolute	Relative
1-mth	-8.1%	-13.5%
3-mth	-27.3%	-35.9%
6-mth	-6.8%	-20.8%

Source: Bloomberg

12-mth Price Performance



Auditor: Ruihua



Earnings Revision

Figure 1: Earnings revisions

guid	Nev	N	Old	ł	Diff (%)		
RMB mn	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E	
Revenue	84,439	102,551	76,661	93,097	10%	10%	
Gross Profit	14,307	17,382	12,978	15,645	10%	11%	
Operating Profit	5,082	6,173	4,361	5,216	17%	18%	
Net profit	4,384	5,329	3,731	4,466	18%	19%	
EPS (RMB)	1.34	1.63	1.15	1.38	16%	18%	
Gross Margin	16.9%	16.9%	16.9%	16.8%	0 ppt	0.1 ppt	
Operating Margin	6.0%	6.0%	5.7%	5.6%	0.3 ppt	0.4 ppt	
Net Margin	5.2%	5.2%	4.9%	4.8%	0.3 ppt	0.4 ppt	

Source: Bloomberg, CMBIS estimates

Figure 2: CMBIS estimates vs consensus

	СМВ	IS	Conser	nsus	Diff (%)		
RMB mn	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E	
Revenue	84,439	102,551	72,133	89,248	17%	15%	
Gross Profit	14,307	17,382	12,074	14,871	18%	17%	
Operating Profit	5,082	6,173	4,787	6,016	6%	3%	
Net profit	4,384	5,329	4,012	4,951	9%	8%	
EPS (RMB)	1.34	1.63	1.20	1.52	11%	7%	
Gross Margin	16.9%	16.9%	16.7%	16.7%	0.2 ppt	0.3 ppt	
Operating Margin	6.0%	6.0%	6.6%	6.7%	-0.6 ppt	-0.7 ppt	
Net Margin	5.2%	5.2%	5.6%	5.5%	-0.4 ppt	-0.4 ppt	

Source: Bloomberg, CMBIS estimates

Figure 3: Revenue breakdown

RMB mn	FY18	FY19	FY20E	FY21E	FY22E
Precision component	9,931	10,620	12,788	14,409	16,068
YoY	-4%	7%	20%	13%	12%
Speaker/Receiver	6,500	6,175	7,410	8,151	8,559
MIC (ECM/MEMS)	2,200	2,860	3,289	3,618	4,161
MEMS sensor	300	330	380	417	459
Antenna	300	390	585	761	989
Optical component module	631	865	1,125	1,462	1,901
Hearable products	6,813	14,823	24,452	43,780	54,017
YoY	25%	118%	65%	79%	23%
AirPods	2,240	9,347	16,365	33,163	40,950
Android TWS	1,000	1,400	3,000	4,680	6,000
Smart Speakers	500	850	1,700	2,380	3,332
Other smart products	6,627	8,514	13,535	18,728	24,194
YoY	-29%	28%	59%	38%	29%
Smart Watch	2,000	3,000	5,100	7,650	10,328
VR/AR	3,000	3,300	6,000	8,400	10,920
Robotics/UAV/smart light	1,627	2,214	2,435	2,678	2,946
Non-main business	380	1,191	6,837	7,521	8,273
YoY	-13%	214%	474%	10%	10%
Total	23,751	35,148	57,613	84,439	102,551
YoY	-7%	48%	64%	47%	21%

Source: Company data, CMBIS estimates



Figure 4: P&L forecast

RMB mn	FY18	FY19	1Q20	2Q20	3Q20	4Q20E	FY20E	FY21E	FY22E
Revenue	23,751	35,148	6,474	9,099	19,157	22,882	57,613	84,439	102,551
YoY	-7%	48%	13%	16%	81%	108%	64%	47%	21%
Cost of sales	(19,282)	(29,726)	(5,294)	(7,470)	(15,828)	(19,111)	(47,703)	(70,132)	(85,169)
Gross profit	4,469	5,422	1,180	1,629	3,329	3,771	9,909	14,307	17,382
GPM (%)	18.8%	15.4%	18.2%	17.9%	17.4%	16.5%	17.2%	16.9%	16.9%
YoY	-20%	21%	23%	41%	87%	147%	83%	44%	21%
SG&A	(1,609)	304	(352)	(311)	(601)	(1,213)	(2,477)	(3,631)	(4,410)
% of rev	6.8%	0.9%	5.4%	3.4%	3.1%	5.3%	4.3%	4.3%	4.3%
R&D	(1,334)	(1,807)	(338)	(635)	(1,072)	(1,124)	(3,169)	(4,560)	(5,538)
% of rev	5.6%	5.1%	5.2%	7.0%	5.6%	4.9%	5.5%	5.4%	5.4%
Operating profit	1,006	1,496	360	618	1,411	929	3,318	5,082	6,173
OPM (%)	4.2%	4.3%	5.6%	6.8%	7.4%	4.1%	5.8%	6.0%	6.0%
YoY	-60%	49%	46%	53%	158%	212%	122%	53%	21%
Net profit	868	1,281	294	487	1,236	838	2,855	4,384	5,329
NPM (%)	3.7%	3.6%	4.5%	5.3%	6.4%	3.7%	5.0%	5.2%	5.2%
YoY	-59%	48%	45%	52%	168%	184%	123%	54%	22%

Source: Company data, CMBIS estimates

Valuation

Maintain BUY with new TP of RMB46.9 (40% upside)

We raised FY21-22E EPS by 16-18% to reflect stronger sales and revised margins. Our new TP of RMB46.9 is based on lowered 35x FY21E P/E (vs 40x prior). Following recent correction on concerns over mgmt. changes, we think the stock is attractive at 24.8x FY21E P/E, given 36% FY20-22E EPS CAGR, strong earnings visibility and improving ROE.

Figure 5: Peers' valuation

		Market			Up/						
		Сар	Price	TP	Down						
Ticker	Rating	US\$(mn)	(LC)	(LC)	-side	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E
nents											
002241 CH	Buy	17,155	33.20	46.9	41%	37.3	24.8	6.0	5.0	15.6	20.3
002475 CH	Buy	57,796	53.10	74.2	40%	39.9	30.0	10.1	7.7	25.2	25.8
002456 CH	NR	4,309	10.28	NA	NA	23.9	17.0	2.6	2.3	10.2	13.7
300136 CH	NR	4,835	32.12	NA	NA	23.8	16.3	5.1	3.9	22.1	25.0
000725 CH	NR	33,036	6.18	NA	NA	47.2	22.0	2.2	2.0	4.0	8.2
002008 CH	NR	7,115	42.86	NA	NA	40.2	27.5	4.6	4.1	12.2	15.4
300433 CH	NR	25,841	33.40	NA	NA	33.3	25.5	5.2	4.5	15.6	16.7
300115 CH	NR	4,057	26.06	NA	NA	41.1	26.2	4.7	4.1	12.2	16.9
002217 CH	NR	1,740	3.59	NA	NA	-	-	-	-	-	-
		Average				36.6	24.2	5.1	4.2	14.4	17.5
nents											
6088 HK	Buy	2,943	3.31	4.1	24%	17.5	12.1	1.3	1.2	7.3	9.8
2018 HK	Hold	6,570	42.15	43.2	2%	34.7	23.2	2.3	2.1	6.5	9.3
2382 HK	Buy	28,888	204.20	146.1	-28%	46.7	34.5	12.1	9.4	26.0	27.1
698 HK	Buy	443	0.53	0.6	6%	10.8	6.6	0.5	0.5	4.7	7.7
285 HK	Buy	15,606	53.70	49.5	-8%	19.7	17.6	5.0	4.0	25.1	22.4
1478 HK	Buy	2,389	15.80	16.6	5%	20.8	17.2	4.6	3.7	22.0	21.8
2283 HK	Buy	311	2.89	2.3	-19%	5.2	4.5	1.9	1.9	35.7	41.7
732 HK	NR	581	1.37	NA	NA	-	-	-	-	-	-
981 HK	NR	37,260	26.45	NA	NA	46.7	81.2	1.7	1.8	4.8	2.3
6869 HK	NR	1,951	10.10	NA	NA	9.8	8.6	0.7	0.7	7.1	7.0
1415 HK	NR	628	5.84	NA	NA	10.6	8.7	2.5	2.3	21.1	29.5
		Average				22.3	21.4	3.3	2.7	15.2	17.1
	002241 CH 002475 CH 002475 CH 002456 CH 300136 CH 000725 CH 002008 CH 300433 CH 300115 CH 002217 CH 002217 CH 0028 CH 300433 CH 300115 CH 002217 CH	002241 CH Buy 002475 CH Buy 002475 CH Buy 002456 CH NR 300136 CH NR 000725 CH NR 002008 CH NR 300433 CH NR 300115 CH NR 002217 CH NR	Ticker Rating US\$(mn) nents 002241 CH Buy 17,155 002475 CH Buy 57,796 002456 CH NR 4,309 300136 CH NR 33,036 002008 CH NR 7,115 300433 CH NR 25,841 300115 CH NR 4,057 002217 CH NR 1,740 Average nents 6088 HK Buy 2,943 2018 HK Hold 6,570 2382 HK Buy 28,888 698 HK Buy 2,848 698 HK Buy 443 285 HK Buy 15,606 1478 HK Buy 2,389 2283 HK Buy 311 732 HK NR 581 981 HK NR 37,260 6869 HK NR 1,951 1415 HK NR 628	Ticker Rating US\$(mn) (LC) nents 002241 CH Buy 17,155 33.20 002475 CH Buy 57,796 53.10 002456 CH NR 4,309 10.28 300136 CH NR 33,036 6.18 002008 CH NR 7,115 42.86 300433 CH NR 25,841 33.40 300115 CH NR 4,057 26.06 002217 CH NR 1,740 3.59 Average nents 6088 HK Buy 2,943 3.31 2018 HK Hold 6,570 42.15 2382 HK Buy 28,888 204.20 698 HK Buy 443 0.53 285 HK Buy 15,606 53.70 1478 HK Buy 2,389 15.80 2283 HK Buy 2,389 15.80 732 HK NR 581 1.37 981 HK NR 37,260 26.45 6869 HK NR 1,951 10.10 1415 HK NR 628 5.84	Ticker Rating US\$(mn) (LC) (LC) nents 002241 CH Buy 17,155 33.20 46.9 002475 CH Buy 57,796 53.10 74.2 002456 CH NR 4,309 10.28 NA 300136 CH NR 4,835 32.12 NA 000725 CH NR 33,036 6.18 NA 002008 CH NR 7,115 42.86 NA 300433 CH NR 25,841 33.40 NA 300115 CH NR 4,057 26.06 NA 002217 CH NR 1,740 3.59 NA Average nents 6088 HK Buy 2,943 3.31 4.1 2018 HK Hold 6,570 42.15 43.2 2382 HK Buy 28,888 204.20 146.1 698 HK Buy 443 0.53 0.6 285 HK Buy 15,606 53.70 49.5 1478 HK Buy 2,389 15.80 16.6 2283 HK Buy 2,389 15.80 16.6 2283 HK Buy 311 2.89 2.3 732 HK NR 581 1.37 NA 981 HK NR 37,260 26.45 NA 6869 HK NR 1,951 10.10 NA 1415 HK NR 1,951 10.10 NA	Ticker Rating US\$(mn) (LC) (LC) -side 10	Ticker Rating US\$(mn) (LC) (LC) -side FY20E Nents	Ticker Rating US\$(mn) (LC) TP Down (LC) P/E (x) nents 002241 CH Buy 17,155 33.20 46.9 41% 37.3 24.8 002475 CH Buy 57,796 53.10 74.2 40% 39.9 30.0 002456 CH NR 4,309 10.28 NA NA 23.9 17.0 300136 CH NR 4,835 32.12 NA NA 23.8 16.3 000725 CH NR 33,036 6.18 NA NA 47.2 22.0 002008 CH NR 7,115 42.86 NA NA 40.2 27.5 300433 CH NR 25,841 33.40 NA NA 41.1 26.2 002217 CH NR 1,740 3.59 NA NA 41.1 26.2 002217 CH NR 1,740 3.59 NA NA 7.5 12.1 2018 HK <t< td=""><td>Ticker Rating US\$(mn) Price (LC) TP (LC) Down (LC) FY20E FY21E FY20E Nents 002241 CH Buy 17,155 33.20 46.9 41% 37.3 24.8 6.0 002475 CH Buy 57,796 53.10 74.2 40% 39.9 30.0 10.1 002456 CH NR 4,309 10.28 NA NA 23.9 17.0 2.6 300136 CH NR 4,835 32.12 NA NA 23.8 16.3 5.1 000725 CH NR 33,036 6.18 NA NA 47.2 22.0 2.2 002008 CH NR 7,115 42.86 NA NA 40.2 27.5 4.6 300433 CH NR 25,841 33.40 NA NA 41.1 26.2 4.7 002217 CH NR 1,740 3.59 NA NA 41.1 24.6 17.5 12.1</td><td>Ticker Rating US\$(mn) (LC) TP Down P/E (x) FY21E FY20E FY21E Nents 002241 CH Buy 17,155 33.20 46.9 41% 37.3 24.8 6.0 5.0 002475 CH Buy 57,796 53.10 74.2 40% 39.9 30.0 10.1 7.7 002456 CH NR 4,309 10.28 NA NA 23.9 17.0 2.6 2.3 300136 CH NR 4,835 32.12 NA NA 23.8 16.3 5.1 3.9 000725 CH NR 33,036 6.18 NA NA 47.2 22.0 2.2 2.0 002008 CH NR 7,115 42.86 NA NA 40.2 27.5 4.6 4.1 300433 CH NR 4,057 26.06 NA NA 41.1 26.2 4.7 4.1 002217 CH NR</td><td>Ticker Rating US\$(mn) (LC) (LC) -side FY20E FY21E FY20E FY21E FY20E FY21E FY20E Nents 002241 CH Buy 17,155 33.20 46.9 41% 37.3 24.8 6.0 5.0 15.6 002475 CH Buy 57,796 53.10 74.2 40% 39.9 30.0 10.1 7.7 25.2 002456 CH NR 4,309 10.28 NA NA 23.9 17.0 2.6 2.3 10.2 300136 CH NR 4,835 32.12 NA NA 23.8 16.3 5.1 3.9 22.1 000725 CH NR 33,036 6.18 NA NA 47.2 22.0 2.2 2.0 4.0 00208 CH NR 7,115 42.86 NA NA 40.2 27.5 4.6 4.1 12.2 300433 CH NR 25,841 33.40 NA NA 40.2 27.5 4.6 4.1 12.2 300433 CH NR 4,057 26.06 NA NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 6. 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.</td></t<>	Ticker Rating US\$(mn) Price (LC) TP (LC) Down (LC) FY20E FY21E FY20E Nents 002241 CH Buy 17,155 33.20 46.9 41% 37.3 24.8 6.0 002475 CH Buy 57,796 53.10 74.2 40% 39.9 30.0 10.1 002456 CH NR 4,309 10.28 NA NA 23.9 17.0 2.6 300136 CH NR 4,835 32.12 NA NA 23.8 16.3 5.1 000725 CH NR 33,036 6.18 NA NA 47.2 22.0 2.2 002008 CH NR 7,115 42.86 NA NA 40.2 27.5 4.6 300433 CH NR 25,841 33.40 NA NA 41.1 26.2 4.7 002217 CH NR 1,740 3.59 NA NA 41.1 24.6 17.5 12.1	Ticker Rating US\$(mn) (LC) TP Down P/E (x) FY21E FY20E FY21E Nents 002241 CH Buy 17,155 33.20 46.9 41% 37.3 24.8 6.0 5.0 002475 CH Buy 57,796 53.10 74.2 40% 39.9 30.0 10.1 7.7 002456 CH NR 4,309 10.28 NA NA 23.9 17.0 2.6 2.3 300136 CH NR 4,835 32.12 NA NA 23.8 16.3 5.1 3.9 000725 CH NR 33,036 6.18 NA NA 47.2 22.0 2.2 2.0 002008 CH NR 7,115 42.86 NA NA 40.2 27.5 4.6 4.1 300433 CH NR 4,057 26.06 NA NA 41.1 26.2 4.7 4.1 002217 CH NR	Ticker Rating US\$(mn) (LC) (LC) -side FY20E FY21E FY20E FY21E FY20E FY21E FY20E Nents 002241 CH Buy 17,155 33.20 46.9 41% 37.3 24.8 6.0 5.0 15.6 002475 CH Buy 57,796 53.10 74.2 40% 39.9 30.0 10.1 7.7 25.2 002456 CH NR 4,309 10.28 NA NA 23.9 17.0 2.6 2.3 10.2 300136 CH NR 4,835 32.12 NA NA 23.8 16.3 5.1 3.9 22.1 000725 CH NR 33,036 6.18 NA NA 47.2 22.0 2.2 2.0 4.0 00208 CH NR 7,115 42.86 NA NA 40.2 27.5 4.6 4.1 12.2 300433 CH NR 25,841 33.40 NA NA 40.2 27.5 4.6 4.1 12.2 300433 CH NR 4,057 26.06 NA NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 41.1 26.2 4.7 4.1 12.2 00217 CH NR 1,740 3.59 NA NA 6. 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.

Source: Bloomberg, CMBIS estimates




Figure 6: 12M forward P/E band



Source: Company data, CMBIS

Figure 7: 12M forward P/B band



Source: Company data, CMBIS

Revenue

Cost of sales

Gross profit



5,328

1,682

646

4,383

1,512

533

FY18A FY19A FY20E FY21E FY22E

2,853

1,319

421

1,542 (2,552) (2,502) (1,835)

1,279

1,992

638

844

1,635

(866)

663

Financial Summary

FY18A FY19A FY20E FY21E

5,422

19,282

4,469

23,751 35,148 57,613 84,439 102,551

29,726 47,703 70,132 85,169

9,909 14,307

Income statement
YE 31 Dec (RMB mn)

						Others	003	030	421	555	040
Selling exp	569	534	1,037	1,520	1,846	Net cash from operating	2,276	5,451	2,041	3,925	5,821
Admin exp (excl. R&D)	1,040	838	1,440	2,111	2,564						
R&D exp	1,334	1,807	3,169	4,560	5,538	Capex	4,240	3,177	3,000	3,000	3,000
Finance costs	318	364	421	533	646	Other	(8,503)	(6,215)	(6,000)	(6,000)	(6,000)
Other operating exp.	201	383	525	500	616	Net cash from investing	(4,263)	(3,038)	(3,000)	(3,000)	(3,000)
Operating profit	1,006	1,496	3,318	5,082	6,173	•					
						Share issuance	16	1	0	0	0
Other non-oper exp.	(13)	(25)	(25)	(25)	(25)	Dividend paid	522	595	707	1,086	1,320
Pre-tax profit	993	1,472	3,293	5,058	6,148	Other	92	(1,933)	165	(705)	(1,285)
						Net cash from financing	630	(1,337)	872	381	35
Income tax expense	149	192	439	675	820						
Minority interests	(23)	(1)	(1)	(1)	(1)	Net change in cash	(1,356)	1,077	(87)	1,306	2,855
Net profit to shareholders	868	1,281	2,855	4,384	5,329	Cash at beginning of the year	3,358	2,008	3,095	3,008	4,314
						Exchange difference	6	10	0	0	C
						Cash at the end of the year	2,008	3,095	3,008	4,314	7,169
Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY18A	FY19E	FY20E		FY22E	YE 31 Dec	FY18A	FY19E	FY20E	FY21E	FY22E
Current assets	13,820	17,704	26,751	35,514	42,984	Sales mix (%)					
Cash & equivalents	2,392	3,613	3,526	4,832	7,687	Precision Components	42	30	22	17	16
Account receivables	7,211	8,147	13,680	17,680	20,388	Hearable products	29	42	42	52	53
Inventories	3,549	5,296	8,898	12,354	14,261	Other smart products	28	24	23	22	24
Prepayment	161	218	218	218	218	Non-main business	2	3	12	9	8
Other current assets	508	429	429	429	429						
						Growth (%)					
Non-current assets	15,922	•	18,638	•	21,444	Revenue	(7.0)	48.0	63.9	46.6	21.5
PPE	-	11,502		14,672	15,990	Gross profit	(20.5)	21.3	82.8	44.4	21.5
Deferred income tax	205	198	198	198	198	Operating profit	(59.7)	48.7	121.7	53.2	21.5
Other non-current assets	4,600	5,256	5,256	5,256	5,256	Net profit	(59.4)	47.6	122.9	53.6	21.6
Total assets	29,742	34,660	45,389	55,640	64,428						
						Profit & loss ratio (%)					
Current liabilities	13,453	17,558	26,140	33,094	37,874	Gross margin	18.8	15.4	17.2	16.9	16.9
Deferred income	104	105	105	105	105	Operating margin	4.2	4.3	5.8	6.0	6.0
Account payables	5,615	9,675	16,257	•	23,991	Net profit margin	3.7	3.6	5.0	5.2	5.2
Tax payable	91	140	140	140	140						
Other current liabilities	7,642	7,639	9,639	11,639	13,639	Balance sheet ratio					
						Net debt/total equity (x)	0.4	0.2	0.3	0.4	0.3
	1,100	973	973	973	973	Current ratio (x)	1.0	1.0	1.0	1.1	1.1
Non-current liabilities		397	397	397	397	Receivable turnover days	104	80	80	80	80
Deferred income	284			233	233	Inventory turnover days	62	54	54	54	54
	209	233	233			,					
Deferred income	209 606	344	344	344	344	Payable turnover days	100	94	94	94	94
Deferred income Deferred tax liability	209 606	344		344	344 38,848	Payable turnover days	100	94	94	94	94
Deferred income Deferred tax liability Other non-current liabilities Total liabilities	209 606	344	344	344		Payable turnover days Profitability (%)	100 5.7		94 15.6	94 20.3	
Deferred income Deferred tax liability Other non-current liabilities	209 606 14,553 3,245	344 18,531 3,245	344 27,113	344 34,067 3,245	38,848	Payable turnover days Profitability (%) ROE		7.9			20.8
Deferred income Deferred tax liability Other non-current liabilities Total liabilities Share capital Reserves	209 606 14,553 3,245 11,956	344 18,531 3,245	344 27,113 3,245	344 34,067 3,245	38,848 3,245	Payable turnover days Profitability (%) ROE	5.7	7.9	15.6	20.3	20.8
Deferred income Deferred tax liability Other non-current liabilities Total liabilities Share capital Reserves Minority interest	209 606 14,553 3,245 11,956 (12)	344 18,531 3,245 12,862 22	344 27,113 3,245 15,010 21	344 34,067 3,245 18,308 19	38,848 3,245 22,318 18	Payable turnover days Profitability (%) ROE ROA	5.7	7.9	15.6	20.3	20.8
Deferred income Deferred tax liability Other non-current liabilities Total liabilities Share capital Reserves	209 606 14,553 3,245 11,956 (12) 15,190	344 18,531 3,245 12,862 22 16,129	344 27,113 3,245 15,010	344 34,067 3,245 18,308 19 21,573	38,848 3,245 22,318 18	Payable turnover days Profitability (%) ROE ROA Per share data (RMB)	5.7	7.9 3.7	15.6	20.3	94 20.8 8.3

Cash flow summary
YE 31 Dec (RMB mn)

Depreciation/amortization

Change in working capital

Net profit

Others

FY22E

17,382



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Disclaimer

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

CMBIS Ratings

BUY
Stock with potential return of over 15% over next 12 months
Control Stock with potential return of +15% to -10% over next 12 months
Control Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-recipiered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.